艰难梭菌疫苗及血清免疫球蛋白G对毒素A的抗体反应。
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
作者信息
Aboudola Samer, Kotloff Karen L, Kyne Lorraine, Warny Michel, Kelly Eoin C, Sougioultzis Stavros, Giannasca Paul J, Monath Thomas P, Kelly Ciarán P
机构信息
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
Abstract
There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.
摘要
血清对毒素A的抗体反应与预防艰难梭菌腹泻之间存在密切关联。一种肠道外注射的艰难梭菌类毒素疫苗在健康志愿者血清中诱导出了对抗毒素A免疫球蛋白G（IgG）的非常高水平的反应。接种疫苗后，所有30名接受者血清中的抗毒素A IgG浓度均超过了先前临床研究中与保护作用相关的浓度。此外，试验组血清抗毒素A IgG的中位数浓度比先前的阈值高50倍。这些发现支持了使用疫苗保护高危个体免受艰难梭菌相关性腹泻和结肠炎侵害的可行性。
相似文献
1
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
2
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.
3
Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.
4
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.
Vaccine. 2009 Jun 2;27(27):3598-604. doi: 10.1016/j.vaccine.2009.03.058. Epub 2009 Apr 9.
5
Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
PLoS One. 2013 Sep 10;8(9):e74452. doi: 10.1371/journal.pone.0074452. eCollection 2013.
6
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
Infect Immun. 1995 Dec;63(12):4619-27. doi: 10.1128/iai.63.12.4619-4627.1995.
7
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.
8
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
9
The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.
10
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
Infect Immun. 1999 May;67(5):2145-52. doi: 10.1128/IAI.67.5.2145-2152.1999.
引用本文的文献
1
De novo design of mini-protein binders broadly neutralizing Clostridioides difficile toxin B variants.
Nat Commun. 2024 Oct 2;15(1):8521. doi: 10.1038/s41467-024-52582-1.
2
Mucosal Vaccination Strategies against Infection.
Vaccines (Basel). 2023 Apr 23;11(5):887. doi: 10.3390/vaccines11050887.
3
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against .
Microorganisms. 2021 Feb 2;9(2):306. doi: 10.3390/microorganisms9020306.
4
A Replicating Single-Cycle Adenovirus Vaccine Effective against .
Vaccines (Basel). 2020 Aug 22;8(3):470. doi: 10.3390/vaccines8030470.
5
Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for .
Vaccines (Basel). 2019 Nov 8;7(4):180. doi: 10.3390/vaccines7040180.
6
Intravenous immunoglobulin therapy for refractory toxin colitis in chronic kidney disease: case reports and literature review.
NDT Plus. 2008 Feb;1(1):20-22. doi: 10.1093/ndtplus/sfm008. Epub 2007 Dec 19.
7
Development of a subunit vaccine for prevention of associated diseases: Biophysical characterization of toxoids A and B.
Biochem Biophys Rep. 2017 Jan 5;9:193-202. doi: 10.1016/j.bbrep.2016.12.015. eCollection 2017 Mar.
8
Treatment of Recurrent Diarrhea.
Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.
9
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
PLoS One. 2017 Jan 26;12(1):e0170640. doi: 10.1371/journal.pone.0170640. eCollection 2017.
10
Clostridium difficile infection: Updates in management.
Indian J Gastroenterol. 2017 Jan;36(1):3-10. doi: 10.1007/s12664-016-0719-z. Epub 2016 Dec 20.
本文引用的文献
1
Prospects for a vaccine for Clostridium difficile.
BioDrugs. 1998 Sep;10(3):173-81. doi: 10.2165/00063030-199810030-00001.
2
Clinical practice. Antibiotic-associated diarrhea.
N Engl J Med. 2002 Jan 31;346(5):334-9. doi: 10.1056/NEJMcp011603.
3
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.
Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):528-34. doi: 10.1007/s100960100550.
4
Clostridium difficile.
Gastroenterol Clin North Am. 2001 Sep;30(3):753-77, ix-x. doi: 10.1016/s0889-8553(05)70209-0.
5
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.
Ann Intern Med. 2001 Sep 18;135(6):434-8. doi: 10.7326/0003-4819-135-6-200109180-00012.
6
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
7
Role of antibody response in outcome of antibiotic-associated diarrhoea.
Lancet. 2001 Jan 20;357(9251):158-9. doi: 10.1016/S0140-6736(00)03582-0.
8
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.
Infect Immun. 2001 Feb;69(2):988-95. doi: 10.1128/IAI.69.2.988-995.2001.
9
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.
Infect Immun. 2000 Oct;68(10):5480-7. doi: 10.1128/IAI.68.10.5480-5487.2000.
10
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.
J Clin Microbiol. 2000 Apr;38(4):1696-7. doi: 10.1128/JCM.38.4.1696-1697.2000.
Zotero 插件